Chiara Tarantelli, David Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J Arribas, Shivaprasad Manjappa, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Giorgio Inghirami, Patrick H Van Berkel, Davide Rossi, Paolo F Caimi, Francesca Zammarchi, Francesco Bertoni
Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through a protease cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer warhead (SG3199). Based on the results of a phase 2 study, loncastuximab tesirine was recently approved for adult patients with relapsed/refractory large B-cell lymphoma. We assessed the activity of loncastuximab tesirine using in vitro and in vivo models of lymphomas, correlated its activity with CD19 expression levels, and identified combination partners providing synergy with loncastuximab tesirine...
May 9, 2024: Haematologica